New drug study for advanced prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This trial tests an experimental new drug (GSK5471713) for men with advanced prostate cancer that has spread and stopped responding to hormone therapy. It is for people who have already tried certain hormone treatments and chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your prostate cancer has spread to other parts of the body (metastatic) and is no longer responding to hormone therapy (castration-resistant).
- You must have a specific type of prostate cancer called adenocarcinoma (the most common type).
- You have already tried at least one type of hormone therapy (ARPI) and have received 1–2 rounds of a chemotherapy called taxane.
- You are generally healthy enough for daily activities (ECOG score 0 or 1).
- You do not have serious heart problems, uncontrolled infections, or other major health conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental drug, alone or with other treatments, for men with advanced prostate cancer that has stopped responding to standard therapies. The goal is to see if it can shrink tumors or slow the disease.
This early-phase trial tests a new study drug called ACE-232 for men with advanced prostate cancer that has stopped responding to standard hormone therapy and chemotherapy. It aims to see if the drug is safe and may help slow the cancer.
This study tests a new drug called JNJ-98768111 in people with advanced prostate cancer that has spread and is no longer responding to current hormone-based treatments. It aims to see if the drug is safe and effective, and participants will receive the study drug while continuing some standard hormone therapy.
This trial tests an experimental drug, GLR2037, for men with advanced prostate cancer that has spread to the bones or soft tissue and has progressed despite prior treatments. The drug may help slow the cancer's growth.
This trial tests a new drug, HSK46575, for men with metastatic castration-resistant prostate cancer that has worsened after hormone therapy and chemotherapy. The goal is to see if it can help slow the cancer's growth.
This trial tests a new drug combination (GZ17-6.02) for men with advanced prostate cancer that has stopped responding to standard hormone therapies. The goal is to see if the drug can help slow down the cancer.
Hear when a new Neoplasms, Prostate trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.